POLE and neoplasm: Biomarker-driven Strategies:Identification of predictive molecular biomarkers for immunotherapy response in MSS CRC, including previously discussed tumor-infiltrating lymphocytes (TILs), POLE/POLD mutations, and tumor mutational burden (TMB).